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A case-control investigation of the relation
between hyperlipidaemia and calcific aortic valve
stenosis
P T Wilmshurst, R N Stevenson, H GriYths, J R Lord
Abstract
Objective—To investigate the relation of
hyperlipidaemia to calcific aortic valve
stenosis.
Design—A case-control study designed to
detect a clinically relevant diVerence in
the fasting plasma concentrations of total
cholesterol between the groups at the 5%
level with a power of 90%. Predefined sub-
group analyses were based on presence of
significant coronary disease and valve
morphology (that is, bicuspid or tricus-
pid).
Setting—A district general hospital.
Subjects—20 patients with severe calcific
aortic stenosis and 20 controls.
Results—Mean (SD) fasting plasma total
cholesterol in patients with aortic stenosis
was 0.79 (1.50) mmol/l greater than in the
controls (p = 0.029). The magnitude of dif-
ferences between patients with aortic
stenosis and controls was similar whether
the patients had coronary artery disease
(0.78 (1.73) mmol/l) or not (0.80 (1.37)
mmol/l). The presence of a stenosed
tricuspid aortic valve was associated with
a significant increase in plasma
cholesterol (1.70 (0.87) mmol/l, p = 0.012).
For bicuspid valves the degree of elevation
of plasma cholesterol was less and not sta-
tistically significant.
Conclusions—Calcific aortic stenosis is
associated with hypercholesterolaemia,
especially when the valve is tricuspid.
Further studies are necessary to confirm
that the relation is causal. This finding
may have implications for measures to
prevent the most common cause of car-
diac valve replacement in the developed
world.
(Heart 1997;78:475–479)
Keywords: calcific aortic stenosis; hypercholesterolae-
mia; hyperlipidaemia
Aortic valve stenosis is the commonest reason
for cardiac valve replacement in the developed
world. In the United Kingdom over half of all
valve replacements are for this reason. The
great majority of cases of aortic stenosis are the
result of calcific valve degeneration. If the
causes of the degenerative process were under-
stood and if eVective preventive measures were
employed the clinical benefits to individual
patients and financial gains for health care pro-
viders would be enormous.
Individuals with bicuspid aortic valves,
which are present in about 1% of the normal
population, are excessively represented among
patients with calcific aortic stenosis and they
have a younger mean age at the time of valve
replacement than patients with stenosed tricus-
pid aortic valves.1 2 This suggests that bicuspid
valves are more susceptible to the degenerative
process than tricuspid valves. The histological
features of stenosis of both bicuspid and
tricuspid valves include calcification, fibrosis,
and lipid deposition with morphological simi-
larities to atherosclerosis.3 A meta-analysis of
33 studies showed a 37% prevalence of
coronary artery disease in patients with calcific
aortic stenosis.4 This greater than anticipated
association suggests the possibility of common
aetiological factors.4 This is supported by
observation that the rate of progression of aor-
tic stenosis on serial Doppler echocardiograms
is faster in those patients with coronary artery
disease.5 The need for coronary grafting at the
time of valve replacement is greater in patients
with a tricuspid valve,2 which suggests that
atherogenic factors may have a more important
role in aortic valve stenosis when the valve is
tricuspid.
In order to determine whether a relation
exists between calcific aortic stenosis and
hypercholesterolaemia we performed a case–
control study. We compared fasting plasma
concentrations of lipids in patients with signifi-
cant aortic stenosis, defined by the need for
valve replacement, and population controls.
The aim of the study was to determine whether
there were clinically relevant diVerences be-
tween the fasting plasma concentrations of
cholesterol and triglyceride in the groups.
Methods
PATIENTS
Patients with calcific aortic stenosis were
included if the degree of stenosis measured
during cardiac catheterisation was severe
enough for valve replacement to be indicated.
In our department the decision to recommend
surgery was based on gradient across the aortic
valve in patients with good left ventricular
function, and on the Gorlin formula—which
uses both valve gradient and flow—in patients
with impaired ventricular contraction.6 The
presence of valve calcification was determined
by fluoroscopy. Patients with haemodynami-
cally important aortic regurgitation or mitral
valve disease were excluded. We considered
that those with mitral valve disease would
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probably have rheumatic heart disease, which
would introduce a confounding factor into the
analysis. Patients were neither included nor
excluded by the presence of significant
coronary artery disease, defined as more than
50% narrowing in one or more coronary arter-
ies on coronary angiography.
CONTROLS
The control subjects were taken from the com-
puter database of a large local group general
practice. For each patient with aortic stenosis,
all the individuals of the same gender and same
age in years were identified by birth date (in
order to prevent bias arising from recognition
of individuals) and one was chosen at random
as the control. The only exclusion criterion for
controls was aortic stenosis, determined by
clinical examination by a cardiologist and con-
firmed by Doppler echocardiographic demon-
stration of an aortic valve gradient in those with
a murmur. Control subjects were not excluded
by the presence of indicators of hyperlipidae-
mia or aortic sclerosis, defined as valve
thickening without stenosis.
All subjects gave informed written consent to
the study, which was approved by the hospital
ethics committee.
LABORATORY ANALYSES
In each case venous blood was sampled after a
12 hour overnight fast, and plasma concentra-
tions of total cholesterol and triglyceride were
measured by standard enzymatic methods
using the Beckman CX7 analyser (Beckman
Instruments, Brea, California, USA). The
between batch coeYcient of variation in our
laboratory is 1.6% for cholesterol and 2.8% for
triglyceride.
STATISTICAL ANALYSIS
A large diVerence in plasma concentrations of
lipids between patients with aortic stenosis and
the rest of the population would be very
obvious and a small diVerence would be clini-
cally irrelevant. A diVerence between the
groups of two or three times the combined
analytical and biological coeYcient of variation
for cholesterol in our population—
approximately 0.7 to 1.05 mmol/l cholesterol—
would be clinically relevant but not immedi-
ately obvious. (The combined analytical and
biological coeYcient of variation for
cholesterol is approximately 6% and the mean
plasma cholesterol concentration in normal
elderly people in our district is approximately 6
mmol/l.) We calculated that 20 patients with
aortic stenosis and 20 case controls would be
suYcient to detect at the 5% level a clinically
relevant diVerence in fasting plasma concentra-
tion of total cholesterol (0.7 to 1.05 mmol/l)
between the groups, with a power of 90%. Pre-
defined subgroup analyses were based on the
presence of significant coronary artery disease
and on aortic valve morphology (that is, deter-
mination of whether the valve was bicuspid or
tricuspid by assessment at the time of valve
replacement). Comparisons between the
groups was with the paired t test (two tailed). A
p value < 0.05 was considered significant.
Results are expressed as mean (SD) or range as
appropriate.
Results
Each group consisted of nine men (mean age
65.4, range 50 to 70 years) and 11 women
(mean age 66.4, range 56 to 75 years).
There was heavy calcification of the aortic
valve in each of the subjects with aortic steno-
sis, and the mean value of peak aortic valve
gradient at the time of cardiac catheterisation
was 74.5 (range 50 to 135) mm Hg. Nine
patients (four men and five women, mean age
64.6, range 50 to 78 years) with aortic stenosis
had significant coronary artery disease (four
single, two double, and three triple vessel
disease) and coronary bypass graft surgery was
planned at the time of valve replacement in
each. Eleven patients (mean age 67.1, range 51
to 75 years) did not have significant coronary
artery disease (nine with absolutely normal
coronary arteries on angiography and two with
minor irregularities), and in none of these was
coronary grafting performed. Two patients did
not have the planned surgery, including the one
with the greatest valve gradient. The reasons
were patient preference in one case and the
concerns of the anaesthetist about coexistent
lung disease in the other. Valve morphology
could not be determined with certainty in these
two cases and in seven other cases the surgeons
were either uncertain or failed to record the
valve morphology. In the remaining cases, six
(mean age 64.2, range 51 to 75 years) had
bicuspid valves and five (mean age 66.2, range
56 to 75 years) had tricuspid valves.
Three control subjects had systolic murmurs
not associated with aortic stenosis. In one case
the murmur was maximal in the mitral area
and echocardiography showed mild mitral
regurgitation and no other abnormality. In two
controls the murmurs were maximal in the
aortic area. Echocardiography in one showed
nodular thickening of the aortic valve without
evidence of stenosis. The other had a normal
echocardiogram. These three individuals were
included as controls because they did not have
predefined exclusions.
Eight controls had findings which suggested
the possibility of hyperlipidaemia. One was an
insulin dependent diabetic, one had a history of
amaurosis fugax (without murmurs or bruits),
one had a subclavian bruit without symptoms,
one had a history of myocardial infarction, one
had polycystic kidneys with hypertension, and
three had essential hypertension.
Both groups were taking a variety of medica-
tions (mean of 2.8 drugs per patient with aor-
tic stenosis and 2.3 drugs per control subject)
from 32 classes of drugs. The drugs most often
taken were non-steroidal anti-inflammatory
drugs (including low dose aspirin), paraceta-
mol and other analgesics, and treatments for
dyspepsia. There was no significant diVerence
between the groups in medication taken
including cardiac drugs; loop diuretics (five
aortic stenosis v two controls), thiazide diuret-
ics (three v three), angiotensin converting
enzyme inhibitors (one v two), â adrenergic
blockers (five v four), class 1 antiarrhythmic
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drugs (one v three), amiodarone (one v none),
dihydropyridines (four v two), or warfarin (one
v none). No subject in either group was taking
lipid lowering drugs.
The results of lipid analysis in the patients
with aortic stenosis and the controls, and the
subgroup analysis, are shown in table 1. Seven-
teen of the patients with aortic stenosis had a
fasting plasma concentration of cholesterol that
was greater than their respective controls. The
mean fasting plasma concentration of total
cholesterol in the patients with aortic stenosis
was higher than in the controls (p = 0.029, dif-
ference = 0.79 (1.50) mmol/l). The mean fast-
ing plasma concentration of total cholesterol in
our control subjects (6.11 mmol/l) was similar
to the anticipated mean concentration for nor-
mal elderly individuals in our district (about 6
mmol/l).
Subgroup analysis showed that the diVer-
ences in cholesterol concentrations between
the patients with aortic stenosis and their con-
trols were similar whether those with aortic
stenosis had coronary artery disease (0.78
(1.73) mmol/l) or not (0.80 (1.37) mmol/l).
These diVerences did not achieve statistical
significance at the 5% level, which may be
related to the small sizes of subgroups. In
patients with aortic stenosis, symptoms were
angina in six of nine with coronary artery
disease and six of 11 without coronary disease.
A further two in the later group had atypical
chest pain. All 14 had dyspnoea on exertion, as
did three without pain. The remaining three,
who all had coronary disease, had no pain or
dyspnoea but complained of syncope, dizzi-
ness, or palpitations. Chest pain was cured by
surgery in all cases—by valve replacement
alone in those patients without coronary
disease.
The fasting plasma concentration of
cholesterol in patients known to have stenosed
tricuspid aortic valves was 1.70 (0.87) mmol/l
higher than in their controls (p = 0.012). In
patients known to have bicuspid aortic valves
the degree of elevation of mean fasting plasma
cholesterol concentration compared with their
controls was less and not significant.
Of the control subjects, the three with mur-
murs had the greatest fasting plasma concen-
trations of cholesterol. If comparisons were
performed after excluding these subjects from
the analysis, the mean diVerence in fasting
plasma cholesterol between the patients with
aortic stenosis and their controls (n = 17)
increased to 1.06 (1.20) mmol/l (p = 0.002).
There was no significant diVerence in
plasma triglyceride concentrations between
patients with aortic stenosis and their controls,
for either the whole groups or the subgroups.
Discussion
With these data we have shown a clinically rel-
evant association between aortic stenosis and
hypercholesterolaemia. This association may
be more important when the valve is tricuspid.
However, an important consideration must be
whether the presence of concomitant coronary
disease in some patients may have produced
symptoms, particularly angina, which
prompted investigation and hence resulted in
bias towards finding an association between
aortic stenosis and hypercholesterolaemia.
Exclusion of patients with coronary artery
disease could itself result in bias. Calcific aortic
stenosis is multifactorial, or at least bifactorial,
because demographic characteristics of pa-
tients with stenosed bicuspid and tricuspid
valves diVer.2 Calcific aortic stenosis is com-
monly associated with coronary disease. In a
meta-analysis of 33 studies reported between
1968 and 1992, significant coronary artery dis-
ease was present in 1302 of 3509 patients with
aortic stenosis (37%).4 This figure is not
dissimilar to the 45% prevalence of coronary
artery disease in patients with aortic stenosis in
our study. Coronary disease is more common
in patients with tricuspid valves.2 Thus in a
study in which only patients with aortic steno-
sis and normal coronaries were studied a false
negative result might be produced by excluding
patients with stenosis of the tricuspid valves,
who a priori might be expected to be the ones
most likely to have hypercholesterolaemia.
Exclusion of patients with symptoms that
may result from coronary disease introduces
other biases. Angina is of course a symptom of
both aortic stenosis and coronary disease. In
our patients this symptom was equally com-
mon in those with and without coronary artery
disease. Every patient studied had symptoms
common to both aortic stenosis and coronary
disease. If only patients with significant aortic
stenosis but without coronary disease or
coronary symptoms were studied, the group
would be so atypical of patients with aortic ste-
nosis that the findings might have little clinical
relevance.
Our data clearly showed that the inclusion of
nine patients with coronary disease and aortic
stenosis did not result in bias. Eight of 20 con-
trols also had conditions which are associated
with hyperlipidaemia, including a history of
myocardial infarction, diabetes mellitus, amau-
rosis fugax, vascular disease, polycystic kidney
disease, and hypertension. Our subgroup
analysis showed that inclusion of cases with
coronary disease did not influence the overall
Table 1 Fasting plasma concentrations of lipids
Aortic stenosis
(mmol/l)
Case controls
(mmol/l)
Mean diVerence
(mmol/l)
Number in
each group p Value
Cholesterol
All AS 6.90 (1.33) 6.11 (1.24) 0.79 (1.50) 20 0.029*
AS + CAD 7.21 (1.32) 6.43 (1.47) 0.78 (1.73) 9 0.21
AS, no CAD 6.65 (1.34) 5.85 (1.02) 0.80 (1.37) 11 0.082
AS bicuspid 6.88 (1.49) 5.90 (1.42) 0.98 (1.34) 6 0.13
AS tricuspid 7.88 (0.64) 6.18 (0.64) 1.70 (0.87) 5 0.012*
Controls, no
murmur 6.78 (1.26) 5.72 (0.85) 1.06 (1.20) 17 0.002*
Triglyceride
All AS 1.61 (0.77) 1.68 (0.90) −0.07 (1.20) 20 0.79
AS + CAD 1.77 (0.81) 1.92 (1.05) −0.15 (1.58) 9 0.78
AS, no CAD 1.48 (0.74) 1.48 (0.76) −0.01 (0.84) 11 0.99
AS bicuspid 1.23 (0.37) 1.18 (0.41) 0.04 (0.23) 6 0.67
AS tricuspid 2.40 (0.80) 1.40 (0.80) 1.00 (0.99) 5 0.09
Controls, no
murmur 1.70 (0.80) 1.61 (0.87) 0.09 (1.18) 17 0.77
*Statistically significant.
AS, aortic stenosis; CAD, coronary artery disease.
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findings. We found that for the whole group of
patients, mean cholesterol was 0.79 (1.50)
mmol/l higher in those with aortic stenosis than
in the controls (p = 0.029, n = 20). In those
with aortic stenosis and coronary disease the
mean cholesterol was 0.78 (1.73) mmol/l
higher than in their controls (p = 0.21, n = 9)
and in those without coronary disease it was
0.80 (1.37) mmol/l higher (p = 0.082, n = 11).
In other words, in both subgroups the findings
were almost identical to the whole.
The results of subgroup analysis might have
been more impressive if we had studied more
patients, but there are two reasons why we did
not. First, there is an ethical imperative in pro-
spective research to perform a power calcula-
tion before the start of a study and then to
study only the number of patients required to
address the primary aim in order to avoid sub-
jecting extra subjects unnecessarily to incon-
venience, pain, or risk. This imperative also
avoids wasting resources by preventing investi-
gators performing more tests than the mini-
mum number required. In addition, if we had
needed to study large numbers to show a
significant diVerence this would suggest that
the eVect was not clinically important.
These data alone do not prove a causal rela-
tion, but in combination with the findings of
others,4 5 7 they suggest that hypercholestero-
laemia may be an aetiological factor in the
development of aortic stenosis. Our findings
suggest that hypercholesterolaemia may be
more important for development of aortic ste-
nosis when the valve morphology is tricuspid.
This is supported by the observation that
coronary artery disease requiring coronary
grafting is more commonly associated with
aortic stenosis when the valve is tricuspid.2 7
Two previous case–control studies have
sought a relation between aortic stenosis and
hypercholesterolaemia, but have produced
conflicting results.8 9 In each of those studies
the degree of aortic stenosis was not severe
enough in all patients to require valve replace-
ment. The controls in both studies were hospi-
tal patients, including those undergoing car-
diac catheterisation for reasons other than
aortic stenosis—including severe coronary ar-
tery disease and unstable angina, and surgical
patients—rather than random population con-
trols. One study failed to show an association
between aortic stenosis and hypercholesterol-
aemia but was biased by exclusion of patients
with aortic stenosis who had coronary artery
disease, yet allowed inclusion of controls with
coronary disease.9 The other study had a
remarkably low proportion (6%) of subjects
who had a definitely bicuspid valve.8 Both
studies used ÷2 tests to compare the subjects
and controls but used diVerent and arbitrary
cholesterol concentrations to subdivide their
groups. Therefore the diVering conclusions of
these two studies may have been the result of
their design. The results obtained were cer-
tainly dependent on choice of cut oVs defining
hypercholesterolaemia. This diYculty was
eliminated in our study by use of absolute
cholesterol concentrations.
A recent report supports the role of hyper-
cholesterolaemia in the aetiology of calcific
aortic stenosis. Rallidis and colleagues reported
a case of calcific aortic stenosis in a 25 year old
woman with homozygous hypercholesterolae-
mia and stated that they had seen five similar
cases (age 14 to 31 years).10 If a severe rise in
plasma cholesterol concentration, to the degree
associated with homozygous hypercholestero-
laemia, for two or three decades can produce
aortic stenosis in some but not all patients, it is
possible that milder degrees of cholesterol
elevation for longer periods might also cause
aortic stenosis. Demonstration of a modest
degree of hypercholesterolaemia on a single
measurement does not prove that an individual
has sustained hypercholesterolaemia, but pro-
spective data from large coronary risk analysis
studies has shown that (oV treatment and
remote from events known to aVect lipid
profiles) the plasma cholesterol concentration
remains constant over many years relative to
the concentrations in peers matched for age
and gender.11 12 If this were not so there would
be no rationale for lipid reduction to modify
coronary risk.
We must also consider whether it is plausible
that the degree of elevation of plasma
cholesterol concentration in our patients, if
sustained, would be suYcient to produce valve
stenosis. For the whole group, plasma
cholesterol concentration was 0.79 (1.50)
mmol/l higher than in the controls, and for
those with stenosis of definitely tricuspid valves
the cholesterol concentration was 1.70 (0.87)
mmol/l higher (p = 0.012). We do not know
whether this degree of hypercholesterolaemia,
if sustained for a number of decades, would
have been suYcient to cause aortic stenosis.
The average age of subjects was 66 years.
Could such an elevation of plasma cholesterol
concentrations for such a period have a
clinically important eVect on a heart valve? We
can draw comparisons from studies of hyper-
cholesterolaemia in coronary artery disease, in
which similar degrees of hypercholesterolaemia
at recruitment were associated with increased
risk of coronary disease at follow up.11 12 In the
Scandinavian simvastatin survival study, re-
ducing total cholesterol by just under 1.7
mmol/l for on average 5.4 years reduced
coronary deaths by 42% and all cause mortality
by 30%.13 In the West of Scotland coronary
prevention study, reducing cholesterol by 1.4
mmol/l for 4.9 years reduced cardiac deaths by
32% and all cause mortality by 22%.14 In both
trials survival curves for placebo and treated
groups started to diverge during the second
year. If lowering cholesterol by about 1.5
mmol/l can have definite eVects on the
endothelium lined coronary arteries within five
years and possible eVects after shorter inter-
vals, it is conceivable that elevation of
cholesterol by a similar magnitude for decades
might aVect endothelium lined cardiac valves.
Further, these trials suggest that if our
observations are extended and confirm a causal
relation, then the degree of cholesterol reduc-
tion one might be seeking to prevent aortic
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valve stenosis is achievable using currently
available treatment.
Proof of a causal relation between hypercho-
lesterolaemia and calcific aortic stenosis could
come from demonstration of an eVect on inci-
dence or progression of aortic stenosis by lipid
reduction in large epidemiological studies. The
studies could be designed to answer that
specific question, or they might be designed to
answer an incidental question, such as the
eVect of cholesterol reduction on coronary dis-
ease progression.14 We may also find that if the
results of primary intervention studies of
hyperlipidaemia are translated into preventive
medical practice, the incidence of aortic steno-
sis is reduced or the age of peak incidence
changes, or both.
1 Davies MJ. Pathology of aortic stenosis in the elderly.Cardiol
Elderly 1995;3:161–5.
2 Davies MJ, Treasure T, Parker DJ. Demographic character-
istics of patients undergoing aortic valve replacement for
stenosis: relation to valve morphology.Heart 1996;75:174–
8.
3 Otto CM, Kuusisto J, Reichenbach DD, Gown AM,
O’Brien KD. Characterization of the early lesions of
“degenerative” valvular aortic stenosis.Circulation 1994;90:
844–53.
4 Mautner GC, Roberts WC. Reported frequency of coronary
arterial narrowing by angiogram in patients with valvular
aortic stenosis. Am J Cardiol 1992;70:539–40.
5 Peter M, HoVman A, Parker C, Luscher T, Burckhardt D.
Progression of aortic stenosis. Role of age and concomitant
coronary artery disease. Chest 1993;103:1715–19.
6 Gorlin R, Gorlin G. Hydraulic formula for calculation of
area of stenotic mitral valve, other cardiac valves and
central circulatory shunts. Am Heart J 1951;41:1–29.
7 Mautner GC, Mautner SL, Cannon RO, Hunsberg SA,
Roberts WC. Clinical factors useful in predicting aortic
valve structure in patients >40 years of age with isolated
valvular aortic stenosis. Am J Cardiol 1993;72:194–8.
8 Deutscher S, Rockette HE, Krishnaswami V. Diabetes and
hypercholesterolaemia among patients with calcific aortic
stenosis. J Chron Dis 1984;37:407–15.
9 Hoagland PM, Cook EF, Flatley M, Walker C, Goldman L.
Case–control analysis of risk factors for presence of aortic
stenosis in adults (age 50 years or older). Am J Cardiol
1985;55:744–7.
10 Rallidis L, Nihoyannopoulos P, Thompson GR. Aortic ste-
nosis in homozygous familial hypercholesterolaemia. Heart
1996;76:84–5.
11 Kannel WB, Castelli WP, Gordon T, McNamara PM.
Serum cholesterol, lipoproteins, and the risk of coronary
heart disease: the Framingham Study. Ann Intern Med
1971;74:1–12.
12 Kannel WB, Neaton JD, Wentworth D, Thomas HE, Stam-
ler J, Hulley SB, et al. Overall and coronary heart disease
mortality rates in relation to major risk factors in 325,348
men screened for the MRFIT. Am Heart J 1986;112:825–
36.
13 Scandinavian Simvastatin Survival Study Group. Ran-
domised trial of cholesterol lowering in 4444 patients with
coronary heart disease: the Scandinavian Simvastatin Sur-
vival Study. Lancet 1994;344:1383–9.
14 Shepherd J, Cobbe SM, Ford I, Isles CG, Lorimer AR,
Macfarlane PW et al. Prevention of coronary heart disease
with pravastatin in men with hypercholesterolemia. N Engl
J Med 1995;333:1301–7.
Hypercholesterolaemia and calcific aortic stenosis 479
 on 13 July 2009 heart.bmj.comDownloaded from 
